ECSP10010234A - Piperazinas como agentes antiobesidad - Google Patents
Piperazinas como agentes antiobesidadInfo
- Publication number
- ECSP10010234A ECSP10010234A EC2010010234A ECSP10010234A ECSP10010234A EC SP10010234 A ECSP10010234 A EC SP10010234A EC 2010010234 A EC2010010234 A EC 2010010234A EC SP10010234 A ECSP10010234 A EC SP10010234A EC SP10010234 A ECSP10010234 A EC SP10010234A
- Authority
- EC
- Ecuador
- Prior art keywords
- piperazinas
- compounds
- antiobesity agents
- preparation
- dyslipidemias
- Prior art date
Links
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 229940125710 antiobesity agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000021017 Weight Gain Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000005861 leptin receptors Human genes 0.000 abstract 1
- 108010019813 leptin receptors Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0702696 | 2007-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010234A true ECSP10010234A (es) | 2010-07-30 |
Family
ID=40409928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010234A ECSP10010234A (es) | 2007-12-05 | 2010-06-04 | Piperazinas como agentes antiobesidad |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20110059969A1 (enExample) |
| EP (1) | EP2229362A1 (enExample) |
| JP (1) | JP2011506294A (enExample) |
| KR (1) | KR20100093104A (enExample) |
| CN (1) | CN102026975A (enExample) |
| AU (1) | AU2008333173A1 (enExample) |
| BR (1) | BRPI0819989A2 (enExample) |
| CA (1) | CA2707555A1 (enExample) |
| CO (1) | CO6280487A2 (enExample) |
| CR (1) | CR11479A (enExample) |
| DO (1) | DOP2010000167A (enExample) |
| EA (1) | EA201000926A1 (enExample) |
| EC (1) | ECSP10010234A (enExample) |
| IL (1) | IL205874A0 (enExample) |
| MX (1) | MX2010006259A (enExample) |
| WO (1) | WO2009071658A1 (enExample) |
| ZA (1) | ZA201003976B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2715527A1 (en) * | 2007-12-05 | 2009-06-11 | Michael Higginbottom | New compounds iv |
| CA2707248A1 (en) * | 2007-12-05 | 2009-06-11 | Astrazeneca Ab | New compounds ii |
| KR101810975B1 (ko) * | 2010-07-08 | 2017-12-20 | 에스케이바이오팜 주식회사 | 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물 |
| EP2683716A1 (en) | 2011-03-11 | 2014-01-15 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| CN113149891B (zh) * | 2020-01-07 | 2024-02-02 | 南京药石科技股份有限公司 | 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法 |
| CN117777048B (zh) * | 2023-09-25 | 2024-09-20 | 上海科利生物医药有限公司 | 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3420193A1 (de) * | 1984-05-30 | 1985-12-05 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel |
| KR20000016402A (ko) | 1996-06-06 | 2000-03-25 | 피터 기딩스 | 렙틴(ob단백질)의 프레그먼트 |
| US6057337A (en) * | 1998-02-02 | 2000-05-02 | Shiseido Co., Ltd. | 1,2-DI-substituted piperidine derivative, hair growth promoter and external composition for skin using the same |
| JP2001131149A (ja) | 1999-11-08 | 2001-05-15 | Sumitomo Pharmaceut Co Ltd | 選択的セロトニン再取り込み阻害剤 |
| JP2001261657A (ja) | 2000-03-17 | 2001-09-26 | Yamanouchi Pharmaceut Co Ltd | シアノフェニル誘導体 |
| BR0114321A (pt) | 2000-09-29 | 2003-07-01 | Glaxo Group Ltd | Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto |
| ES2197003B1 (es) * | 2002-04-08 | 2005-03-16 | J. URIACH & CIA S.A. | Nuevos compuestos antagonistas de integrinas alfa. |
| EP1644347A1 (en) | 2003-06-20 | 2006-04-12 | Arena Pharmaceuticals, Inc. | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES |
| CN102633730A (zh) * | 2004-12-03 | 2012-08-15 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
| DE102005000666B3 (de) | 2005-01-04 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20090325975A1 (en) | 2005-07-15 | 2009-12-31 | Helmut H Buschmann | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
| EP1787679A1 (en) | 2005-07-29 | 2007-05-23 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
| US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| EP1991211A1 (en) | 2006-02-28 | 2008-11-19 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome |
| CA2715527A1 (en) | 2007-12-05 | 2009-06-11 | Michael Higginbottom | New compounds iv |
| CA2707822A1 (en) | 2007-12-05 | 2009-06-11 | Astrazeneca Ab | New compounds iii |
| CA2707248A1 (en) | 2007-12-05 | 2009-06-11 | Astrazeneca Ab | New compounds ii |
| US20110275670A1 (en) | 2008-06-04 | 2011-11-10 | Emma Chapman | New Compounds VII |
| WO2009147211A1 (en) | 2008-06-04 | 2009-12-10 | Biovitrum Ab (Publ) | New compounds v |
| CA2726270A1 (en) | 2008-06-04 | 2009-12-10 | Astrazeneca Ab | Small molecule leptin receptor modulators |
| MX2010013359A (es) | 2008-06-04 | 2011-04-07 | Astrazeneca Ab | Nuevos derivados de piridina como mimeticos moduladores del receptor de leptina. |
-
2008
- 2008-12-05 US US12/744,359 patent/US20110059969A1/en not_active Abandoned
- 2008-12-05 CA CA2707555A patent/CA2707555A1/en not_active Abandoned
- 2008-12-05 EP EP08856144A patent/EP2229362A1/en not_active Withdrawn
- 2008-12-05 BR BRPI0819989 patent/BRPI0819989A2/pt not_active IP Right Cessation
- 2008-12-05 JP JP2010536469A patent/JP2011506294A/ja active Pending
- 2008-12-05 WO PCT/EP2008/066877 patent/WO2009071658A1/en not_active Ceased
- 2008-12-05 US US12/315,698 patent/US7851471B2/en not_active Expired - Fee Related
- 2008-12-05 MX MX2010006259A patent/MX2010006259A/es not_active Application Discontinuation
- 2008-12-05 EA EA201000926A patent/EA201000926A1/ru unknown
- 2008-12-05 CN CN2008801266306A patent/CN102026975A/zh active Pending
- 2008-12-05 KR KR1020107014723A patent/KR20100093104A/ko not_active Withdrawn
- 2008-12-05 AU AU2008333173A patent/AU2008333173A1/en not_active Abandoned
-
2010
- 2010-05-20 IL IL205874A patent/IL205874A0/en unknown
- 2010-06-03 ZA ZA2010/03976A patent/ZA201003976B/en unknown
- 2010-06-04 DO DO2010000167A patent/DOP2010000167A/es unknown
- 2010-06-04 CO CO10068022A patent/CO6280487A2/es not_active Application Discontinuation
- 2010-06-04 CR CR11479A patent/CR11479A/es not_active Application Discontinuation
- 2010-06-04 EC EC2010010234A patent/ECSP10010234A/es unknown
- 2010-11-01 US US12/917,085 patent/US20110046135A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL205874A0 (en) | 2010-11-30 |
| CR11479A (es) | 2010-07-19 |
| US20110046135A1 (en) | 2011-02-24 |
| CA2707555A1 (en) | 2009-06-11 |
| JP2011506294A (ja) | 2011-03-03 |
| US20090181967A1 (en) | 2009-07-16 |
| CO6280487A2 (es) | 2011-05-20 |
| WO2009071658A1 (en) | 2009-06-11 |
| CN102026975A (zh) | 2011-04-20 |
| DOP2010000167A (es) | 2010-06-30 |
| BRPI0819989A2 (pt) | 2015-05-12 |
| MX2010006259A (es) | 2010-08-23 |
| US7851471B2 (en) | 2010-12-14 |
| ZA201003976B (en) | 2011-04-28 |
| KR20100093104A (ko) | 2010-08-24 |
| EA201000926A1 (ru) | 2011-02-28 |
| EP2229362A1 (en) | 2010-09-22 |
| US20110059969A1 (en) | 2011-03-10 |
| AU2008333173A1 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6280487A2 (es) | Piperazinas como agentes antiobesidad | |
| CR11801A (es) | Derivados de indazol sustituidos con fenilo y benzodioxinilo | |
| CL2008002787A1 (es) | Compuestos derivados de piperidina, que presentan actividad moduladora sobre la actividad del receptor gpr 119; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades tales como diabetes tipo 1 y 2, hiperllpidemia, enfermedad coronaria, obesidad y disfuncion erectil. | |
| CR10922A (es) | Derivados de indol como antagonistas receptores de s1p1 | |
| SV2010003580A (es) | Agonistas novedosos de los receptores de glucocorticoides | |
| PA8777101A1 (es) | Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal | |
| CR11455A (es) | Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades | |
| UY30470A1 (es) | Compuestos heteroarilos de cinco heteroatomos sustituidos con fenilo conteniendo nitrogeno, composiciones farmacéuticas y aplicaciones. | |
| ECSP099452A (es) | Derivados de éster y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides | |
| CO6470899A2 (es) | 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal | |
| CO6351723A2 (es) | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1 | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| CR9722A (es) | Derivados de benzilpiperazina y su uso medico | |
| NI201100117A (es) | Antagonistas de 4 -- azetidinil - 1 - heteroaril - ciclohexanol del ccr2. | |
| UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
| PA8806801A1 (es) | Compuestos de amida como refuerzos de antivirales | |
| ECSP109961A (es) | Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica | |
| PA8773601A1 (es) | Agonistas cannabinoides de bencimidazol | |
| NI201100015A (es) | Compuestos novedosos activos como antagonistas de receptor muscarínico. | |
| BRPI0815455C1 (pt) | compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo | |
| UY31143A1 (es) | Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas | |
| MX2010006215A (es) | Derivados de piperazina y su uso como moduladores del receptor de leptina. | |
| CL2008001261A1 (es) | Compuestos derivados de 4-(benzoxanol-2-ilamino), ligandos del receptor npy y5; composiciones farmaceuticas que los contienen; y sus uso en la preparacion de medicamentos utiles en el tratamiento de la depresion, la ansiedad o la obesidad. | |
| MX2010006216A (es) | Nuevos compuestos iii. | |
| AR053691A1 (es) | Agentes endoparasiticidas |